Longeveron (LGVN) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
Laromestrocel remains the lead investigational therapy across four potential indications; strategic and financing alternatives, including a potential business combination, are under review with Lucid Capital Markets as advisor.
ELPIS II missed its primary HLHS efficacy endpoint; an updated analysis found fewer adjudicated events and a statistically significant MACE difference, and an FDA meeting was requested to discuss next steps.
Financial highlights
Q3 2026 revenue was $115K vs. $137K YoY; gross profit was $71K vs. $125K, with lower contract manufacturing revenue contributing to the decline.
Q3 operating loss was $7.2M vs. $7.3M; net loss was $6.1M vs. $7.2M, reflecting $1.0M of XPRIZE Healthspan award income and lower G&A expense.
9M 2026 revenue was $800K vs. $834K; operating loss was $18.1M vs. $17.9M and net loss was $16.9M vs. $17.3M.
9M operating cash use was $12.7M; financing provided $15.5M, lifting cash by $2.6M to $7.2M at September 30, 2026.
Outlook and guidance
Cash and cash equivalents of $7.2M were expected to fund operations into Q1 2027 under current plans and cash-conservation measures; additional capital will be needed to advance development.
Strategic alternatives may include a partnership or investment, additional financing, a sale or merger, or a business combination; no definitive timeline or assured outcome was established.
HLHS next steps depend on FDA review of ELPIS II; proposed AD Phase 2/3 and pediatric DCM trial plans depend on partnerships, funding and strategic review.
Forecasts show insufficient cash to meet minimum expenditure commitments for one year from financial-statement issuance; substantial doubt exists about the ability to continue as a going concern.
Latest events from Longeveron
- ELPIS II topline data are anticipated in Q3 2026 as laromestrocel advances across four indications.LGVN
Investor presentation - ELPIS I showed 100% five-year transplant-free survival in treated HLHS patients.LGVN
Investor presentation - Laromestrocel advances across three indications, with pivotal trials planned or underway.LGVN
Investor presentation - Pivotal HLHS and planned Alzheimer's and PDCM trials anchor laromestrocel's pipeline.LGVN
Investor presentation - Laromestrocel spans three indications, with ELPIS II pivotal if positive.LGVN
Investor presentation - Lomecel-B advances across three indications, with encouraging HLHS, AD and frailty data.LGVN
Investor presentation - Laromestrocel's late-stage data and PRV eligibility position it for major value inflection.LGVN
Investor presentation - Q2 2026 net loss rose to $6.1M as cash runway extends into Q4 2026 ahead of key trial results.LGVN
Q2 2026 - All proposals, including director elections and share amendments, were approved by majority vote.LGVN
AGM 2026